The introduction of new therapeutic drugs typically involves a long and expensive process that may begin with a relatively simple initial discovery but that includes an extended period of development, which addresses formulation, efficacy, safety, and commercial potential. Many constituencies must be involved and satisfied at each step in this process, while the diverse goals and perspectives that each player brings to the enterprise are dealt with. The two main foundations of this activity are academic research and industry; the latter includes both traditional pharmaceutical companies and newer, usually smaller, biotechnology companies. The recognition of the importance and the differing viewpoints of these "two towers" of the intellectual and commercial undertaking may help to foster more effective working relationships among the parties and, ultimately, may increase the efficiency of bringing new therapies to the consumer. An understanding of the process of discovery and development across the disciplines involved may provide a meaningful answer to patients and families who constantly ask, "Why does it take so long?"
Skip Nav Destination
Article navigation
Research Article|
June 09 2004
The Two Towers: Quest for Drugs from Discovery to Approval
Ron Cohen;
Ron Cohen
1
Acorda Therapeutics, Hawthorne, New York.
Search for other works by this author on:
Patrick Potter
Patrick Potter
2
Physical Medicine and Rehabilitation, Lawson Health Research Institute, The University of Western Ontario, London, Ontario, Canada.
Search for other works by this author on:
Top Spinal Cord Inj Rehabil (2004) 10 (1): 63–71.
Citation
Ron Cohen, Patrick Potter; The Two Towers: Quest for Drugs from Discovery to Approval. Top Spinal Cord Inj Rehabil 1 July 2004; 10 (1): 63–71. doi: https://doi.org/10.1310/3ERE-BLAQ-69DK-R6VB
Download citation file:
35
Views
Citing articles via
Behavioral/Physical and Stimulation Interventions for Chronic Pain Following Spinal Cord Injury: A Systematic Review
Linda Ehrlich-Jones, PhD, RN, Elise Olsen, BA, Angelika Kudla, MS, Jennifer Burns, BA, Nicole Sharf, MA, Q. Eileen Wafford, MST, MLIS, Allen W. Heinemann, PhD
Grocery Shopping and Eating Behaviors Differ Between Persons With and Without a Spinal Cord Injury
Zachary J. Donato, MS, MD, Adam S. Levy, MS, MD, Alicia Sneij, PhD, MS, RD, Sherri L. LaVela, PhD, MPH, MBA, Arthur S. Berg, PhD, Lauren T. Shapiro, MD, MPH, Gary J. Farkas, PhD, MSCTI
No Beneficial Effects of the Alfasigma VSL#3 Probiotic Treatment After Cervical Spinal Cord Injury in Rats
Pamela J.F. Raposo, MSc, Antoinette T. Nguyen, PhD, Emma K.A. Schmidt, PhD, Abel Torres Espin, PhD, Keith K. Fenrich, PhD, David J. Bennett, PhD, Karim Fouad, PhD
Perspectives on Barriers to Use and Benefits of Functional Electrical Stimulation From Australians and New Zealanders With SCI and Clinicians and Researchers in the Field
Anne E. Palermo, PT, DPT, PhD, Edward Gorgon, PT, PhD, Antonio Vecchio, BS, Lisa Tedesco Triccas, PT, PhD, Euan McCaughey, PhD, Maggie Donovan-Hall, PhD
Breastfeeding After Spinal Cord Injury: A Systematic Review of Prevalence and Associated Complications
Andrei Krassioukov, MD, PhD, Amanda H.X. Lee, MSc, MD (student), Stacy Elliott, MD, Teri Thorson, Nathan Agon-Chen, BKin, MPT, MD, Gavin Naicker, BSc, MBT, MD (student), Matthew Querée, MAppPsych, Janice Eng, PhD, BSc(PT/OT), SCIRE Team